Klaria Pharma Holding AB (publ.) (STO:KLAR)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.790
-0.010 (-1.25%)
Mar 9, 2026, 5:23 PM CET
-33.61%
Market Cap 194.32M
Revenue (ttm) 8.99M
Net Income (ttm) -38.89M
Shares Out 245.98M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,706
Average Volume 601,078
Open 0.780
Previous Close 0.800
Day's Range 0.722 - 0.842
52-Week Range 0.396 - 1.700
Beta 1.44
RSI 46.56
Earnings Date Feb 20, 2026

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of... [Read more]

Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol KLAR
Full Company Profile

Financial Performance

In 2025, STO:KLAR's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -38.89 million, -18.56% less than in 2024.

Financial Statements

News

There is no news available yet.